Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM for the Treatment of Critical Leg Ischemia|
- Reduction in proportion of subjects who experience a major amputation.
- Reduction in proportion of subjects who die within 6 months from treatment initiation.
- Reduction in major amputation rate only.
- Reduction in critical cardiovascular events.
- Improvement in complete ulcer healing.
- Improvement in pain at rest.
- Improvement in quality of life.
- Improvement in hemodynamic measurements.
- Improvement in neuropathy.
|Study Start Date:||July 2001|
|Estimated Study Completion Date:||June 2004|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00059644
Show 27 Study Locations